Decreased incidence of diabetes in patients with gout using benzbromarone. (22nd May 2018)

• Record Type: Journal Article
• Authors: Niu, Sheng-Wen; Chang, Kai-Ting; Ta, Albert; Chang, Yu-Han; Kuo, I Ching; Hung, Chi-Chih; Chiu, Yi-Wen; Hwang, Shang-Jyh; Lin, Sheng-Fung; Lin, Hugo You-Hsien
• Is Part Of: Rheumatology. Volume 57:Number 9(2018)
• Page Start: 1574
• Page End: 1582
• Publication Date: 2018-05-22
• Subjects: benzbromarone -- diabetes mellitus -- gout; Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/key138
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: Objective: Insulin resistance is inversely correlated with the clearance rate of uric acid, which may indicate that improvement in the clearance rate of uric acid could reduce insulin resistance. Considering the increased prevalence of diabetes mellitus (DM) in the gout population, this study evaluated the effects of benzbromarone, a uricosuric agent, on the incidence of DM in the gout population. Methods: We used data from the Taiwan National Health Insurance program. The benzbromarone user cohort included 8678 patients; each patient was age- and sex-matched with one benzbromarone non-user who was randomly selected from the gout population. The Cox proportional hazard regression analysis was conducted to estimate the effects of benzbromarone on the incidence of DM in the gout population. Results: The incidence of DM was significantly lower in benzbromarone users than in benzbromarone non-users [adjusted hazard ratio (HR) = 0.86; 95% CI: 0.79, 0.94]. The HR for the incidence of DM was lower in male benzbromarone users (adjusted HR = 0.77; 95% CI: 0.69, 0.86) than in benzbromarone non-users. An analysis of three age groups (<40, 40–59 and ⩾60 years) indicated that the HRs of the age groups of 40–59 years (adjusted HR = 0.86; 95% CI: 0.76, 0.98) and ⩾60 years (adjusted HR = 0.82; 95% CI: 0.71, 0.94) were significantly lower among benzbromarone users than among benzbromarone non-users. Conclusion: In the gout population, the incidence of DM was lower in benzbromarone users than in benzbromarone non-users.